Metraipolis › archive › dc_9a034f94be77
Genomic biomarkers of immunotherapy plus chemotherapy in patients with advanced NSCLC: Insights from the phase 3 ORIENT-11 study — Europe PMC PMID:41660271
- Source
- Europe PMC (en)
- Original
- https://europepmc.org/article/MED/41660271
- DOI
- 10.1016/j.isci.2026.114730
- License (as archived)
- solo-consultazione
- Archived
- 2026-11-06T17:20:40.987Z
- SHA-256 of the archived text
e149a2f3cdc073ced9b46994b6d69b06e380d7bb4163ace3352f7846a9815346- Stable URL of this page
https://metraipolis.com/documento/dc_9a034f94be77
How to cite
Genomic biomarkers of immunotherapy plus chemotherapy in patients with advanced NSCLC: Insights from the phase 3 ORIENT-11 study — Europe PMC PMID:41660271 — Europe PMC (en), https://europepmc.org/article/MED/41660271 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_9a034f94be77 (Metraipolis archive dc_9a034f94be77, sha256 e149a2f3cdc073ced9b46994b6d69b06e380d7bb4163ace3352f7846a9815346)
BibTeX
@misc{dc9a034f94be77,
title = {Genomic biomarkers of immunotherapy plus chemotherapy in patients with advanced NSCLC: Insights from the phase 3 ORIENT-11 study — Europe PMC PMID:41660271},
howpublished = {Europe PMC (en)},
url = {https://europepmc.org/article/MED/41660271},
note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_9a034f94be77; sha256 e149a2f3cdc073ced9b46994b6d69b06e380d7bb4163ace3352f7846a9815346},
year = {2026}
}Archived text
The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41660271. Agents can read the archived copy with the MCP tool read_document.